Tau Oligomers in Cerebrospinal Fluid in Alzheimer's Disease

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2017 Apr 7

PMID 28382304

Citations 44

Authors

Urmi Sengupta

Erik Portelius

Oskar Hansson

Kathleen Farmer

Diana Castillo-Carranza

Randall Woltjer

Henrik Zetterberg

Douglas Galasko

Kaj Blennow

Rakez Kayed

Affiliations

Soon will be listed here.

Abstract

Objective: With an increasing incidence of Alzheimer's disease (AD) and neurodegenerative tauopathies, there is an urgent need to develop reliable biomarkers for the diagnosis and monitoring of the disease, such as the recently discovered toxic tau oligomers. Here, we aimed to demonstrate the presence of tau oligomers in the cerebrospinal fluid (CSF) of patients with cognitive deficits, and to determine whether tau oligomers could serve as a potential biomarker for AD.

Methods: A multicentric collaborative study involving a double-blinded analysis with a total of 98 subjects with moderate to severe AD ( = 41), mild AD ( = 31), and nondemented control subjects ( = 26), and two pilot studies of 33 total patients with AD ( = 19) and control ( = 14) subjects were performed. We carried out biochemical assays to measure oligomeric tau from CSF of these patients with various degrees of cognitive impairment as well as cognitively normal controls.

Results: Using a highly reproducible indirect ELISA method, we found elevated levels of tau oligomers in AD patients compared to age-matched controls. Western blot analysis confirmed the presence of oligomeric forms of tau in CSF. In addition, the ratio of oligomeric to total tau increased in the order: moderate to severe AD, mild AD, and controls.

Conclusion: These assays are suitable for the analysis of human CSF samples. These results here suggest that CSF tau oligomer measurements could be optimized and added to the panel of CSF biomarkers for the accurate and early detection of AD.

Citing Articles

Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer's Disease and Other Proteinopathies.

Kotarba S, Kozlowska M, Scios M, Saramowicz K, Barczuk J, Granek Z Int J Mol Sci. 2024; 25(19).

PMID: 39409126 PMC: 11477428. DOI: 10.3390/ijms251910797.

Updates in Alzheimer's disease: from basic research to diagnosis and therapies.

Liu E, Zhang Y, Wang J Transl Neurodegener. 2024; 13(1):45.

PMID: 39232848 PMC: 11373277. DOI: 10.1186/s40035-024-00432-x.

Oligomeric Tau-induced oxidative damage and functional alterations in cerebral endothelial cells: Role of RhoA/ROCK signaling pathway.

Hossen F, Sun G, Lee J Free Radic Biol Med. 2024; 221:261-272.

PMID: 38815773 PMC: 11184584. DOI: 10.1016/j.freeradbiomed.2024.05.044.

The RAGE Axis: A Relevant Inflammatory Hub in Human Diseases.

Rojas A, Lindner C, Schneider I, Gonzalez I, Uribarri J Biomolecules. 2024; 14(4).

PMID: 38672429 PMC: 11048448. DOI: 10.3390/biom14040412.

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology.

Blomeke L, Rehn F, Kraemer-Schulien V, Kutzsche J, Pils M, Bujnicki T Alzheimers Dement (Amst). 2024; 16(2):e12589.

PMID: 38666085 PMC: 11044868. DOI: 10.1002/dad2.12589.

References

Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

Skillback T, Farahmand B, Rosen C, Mattsson N, Nagga K, Kilander L . Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain. 2015; 138(Pt 9):2716-31. DOI: 10.1093/brain/awv181. View

Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, Spillantini M . The role of tau in the pathological process and clinical expression of Huntington's disease. Brain. 2015; 138(Pt 7):1907-18. PMC: 4572485. DOI: 10.1093/brain/awv107. View

Sjogren M, Andreasen N, Blennow K . Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta. 2003; 332(1-2):1-10. DOI: 10.1016/s0009-8981(03)00121-9. View

Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P . Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers. Mech Ageing Dev. 2005; 127(2):129-32. DOI: 10.1016/j.mad.2005.09.022. View

Guzman-Martinez L, Farias G, Maccioni R . Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs. Front Neurol. 2013; 4:167. PMC: 3808896. DOI: 10.3389/fneur.2013.00167. View

Tarawneh R, Holtzman D . The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012; 2(5):a006148. PMC: 3331682. DOI: 10.1101/cshperspect.a006148. View

Babic M, Strac D, Muck-Seler D, Pivac N, Stanic G, Hof P . Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J. 2014; 55(4):347-65. PMC: 4157375. DOI: 10.3325/cmj.2014.55.347. View

10.

Herukka S, Hallikainen M, Soininen H, Pirttila T . CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005; 64(7):1294-7. DOI: 10.1212/01.WNL.0000156914.16988.56. View

11.

Galasko D . Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Front Neurol. 2016; 6:256. PMC: 4680926. DOI: 10.3389/fneur.2015.00256. View

12.

Zetterberg H, Wahlund L, Blennow K . Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett. 2003; 352(1):67-9. DOI: 10.1016/j.neulet.2003.08.011. View

13.

Berti V, Polito C, Lombardi G, Ferrari C, Sorbi S, Pupi A . Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Neurol Sci. 2016; 37(5):663-72. DOI: 10.1007/s10072-016-2477-1. View

14.

Gerson J, Sengupta U, Lasagna-Reeves C, Guerrero-Munoz M, Troncoso J, Kayed R . Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun. 2014; 2:73. PMC: 4229782. DOI: 10.1186/2051-5960-2-73. View

15.

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

16.

Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

17.

Rajan K, Wilson R, Weuve J, Barnes L, Evans D . Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology. 2015; 85(10):898-904. PMC: 4560057. DOI: 10.1212/WNL.0000000000001774. View

18.

Dubois B, Feldman H, Jacova C, DeKosky S, Barberger-Gateau P, Cummings J . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8):734-46. DOI: 10.1016/S1474-4422(07)70178-3. View

19.

Margittai M, Langen R . Template-assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci U S A. 2004; 101(28):10278-83. PMC: 478563. DOI: 10.1073/pnas.0401911101. View

20.

Shaw L, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65(4):403-13. PMC: 2696350. DOI: 10.1002/ana.21610. View